Preclinical Pharmacodynamic and Pharmacokinetic Studies of Investigational New Drugs.
Abstract
During the past year of the contract, a study was initiated to evaluate, in dogs, whether significant clinical or pharmacological interactions occur when single oral doses of the antimalarial drug WR238605 are given in combination with one of the following schizonticidal agents: mefloquine, halofantrine, chloroquine or quinine/doxycycline. An initial pilot experiment was conducted to obtain a profile of the plasma kinetics of each schizonticidal agent alone and in combination with WR238605 in order to establish optimal times for sample collection and physiological evaluations in a subsequent main experiment. No gross adverse physiological effects were observed when WR238605 was undiminished alone or in combination with the individual schizonticidal agents. Analyses of the plasma samples for drug concentrations have not been completed to date. Thus, conclusions relevant to possible kinetic interactions between WR238605 and the other schizonticidal agents cannot be drawn at this time.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 1996
- Accession Number
- ADA320255
Entities
People
- Patricia Noker
Organizations
- Southern Research